STAT
JULY 20, 2024
First Opinion is STAT’s platform for interesting, illuminating, and maybe even provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others. To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected Letters to the Editor received in response to them.
Drug Patent Watch
JULY 20, 2024
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Happy PharmD
JULY 20, 2024
Are you curious about emergency medicine pharmacy and whether or not it’s something that you should consider as a career choice? Well, you’re not alone. Lots of other people have thought the same thing, and in this discussion, we’ll dive into the nitty-gritty details — the pros, the cons, the salary, the satisfaction, the job demand, and of course, the flexibility of having this career path as a pharmacist.
PharmaTech
JULY 20, 2024
PluriCDMO, Pluri's newly launched CMDO division, has been selected by Kadimastem to manufacture two novel cell therapy product candidates.
Speaker: Joe Sharpe and James Carlson
In the world of small business management, the challenge of managing payroll & HR efficiently while scaling operations can be overwhelming. Yet, with the right strategies in place, these challenges can become opportunities for growth and innovation. In this session, Joe Sharpe, Senior Director of Managed Payroll Services at IRIS, will reveal practical methods and expert insights for outsourcing and streamlining payroll processes, resulting in substantial time and resource savings.
Pharmacy Times
JULY 20, 2024
However, the cost of zuranolone makes it challenging to access and justify, given study results comparing it with brexanolone.
Drug Patent Watch
JULY 20, 2024
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Romania.
Expert insights. Personalized for you.
270 
Let's personalize your content